In its report published Monday, Oppenheimer analyst Christopher Marai has boosted the price target of Incyte Corporation (NASDAQ:INCY) stock to $89 (from $75), following the company’s …
In a research report sent to investors today, J.P.
Last week, the S&P 500 put an end to its streak of weekly losses, despite giving back some gains on Friday. Thursday provided …
Agenus, Inc (NASDAQ: AGEN) announced a global alliance with Incyte Corp. (NASDAQ: INCY) to develop cancer therapies.
Incyte Corporation (NASDAQ: INCY) is a $12 billion pharmaceutical company that is expected to finally turn a profit next year on the success of …
Cowen analyst Eric Schmidt maintained an Outperform rating on Incyte (NASDAQ:INCY), following the news that the company’s Jakafi gained FDA approval for the treatment …
In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Incyte (NASDAQ:INCY) and slightly raised his price …
